MBX Biosciences Reports Once-Weekly Canvuparatide Shows Sustained Clinical Benefit for Chronic Hypoparathyroidism Over One Year
Market Chameleon (Mon, 15-Jun 11:55 AM)
MBX’s Canvuparatide Shows 57% One-Year Responder Rate and Strong Safety Profile in Chronic Hypoparathyroidism Study
Market Chameleon (Fri, 12-Jun 9:52 AM)
MBX Biosciences Shows Sustained One-Year Benefit of Once-Weekly Canvuparatide for Chronic Hypoparathyroidism
Market Chameleon (Fri, 12-Jun 8:09 AM)
